中国科学技术大学学报 ›› 2018, Vol. 48 ›› Issue (10): 801-809.DOI: 10.3969/j.issn.0253-2778.2018.10.006

• 原创论文 • 上一篇    下一篇

NLRP3炎症小体抑制剂研究进展

何鸿宾   

  1. 中国科学技术大学生命科学学院,安徽合肥 230027
  • 收稿日期:2018-08-01 修回日期:2018-09-06 出版日期:2018-10-31 发布日期:2018-10-31
  • 通讯作者: 江维
  • 作者简介:何鸿宾,男,1989年生,博士生. 研究方向:固有免疫. E-mail:hhb123@ustc.edu.cn
  • 基金资助:
    国家自然科学基金优秀青年科学基金(81722022),国家重大科学研究计划青年科学家专题项目(2014CB910800)资助.

Research advance of NLRP3 inflammasome inhibitor

HE Hongbin   

  1. School of Life Sciences, University of Science and Technology of China, Hefei 230027, China
  • Received:2018-08-01 Revised:2018-09-06 Online:2018-10-31 Published:2018-10-31

摘要: NLRP3是一种重要的胞内模式识别受体,可以与ASC及pro-caspase-1形成炎症小体,促进IL-1β和IL-18等炎性介质的成熟和分泌,从而促进炎症反应.NLRP3炎症小体活化失调与多种人类重大疾病密切相关,如痛风、动脉粥样硬化、神经退行性疾病和2型糖尿病等.因此NLRP3炎症小体是上述疾病的潜在干预靶点,许多NLRP3炎症小体抑制剂对相关疾病表现出良好的预防或者治疗效果.本文对NLRP3炎症小体抑制剂最近的研究进展进行简要综述.

关键词: NLRP3炎症小体, 疾病, NLRP3炎症小体抑制剂

Abstract: NLRP3 is an important intracellular pattern recognition receptor, which can form inflammasome with ASC and pro-caspase-1. Formation of NLRP3 inflammasome leads to maturity and secretion of inflammatory cytokines, such as IL-1β and IL-18, and then causes the inflammation. Dysregulation of NLRP3 inflammasome is associated with several human diseases, such as gout, atherosclerosis, neurodegenerative diseases and type 2 diabetes, so NLRP3 inflammasome is a potential target for treatment of those diseases, and several NLRP3 inflammasome inhibitors have shown preventive or therapeutic effects on NLRP3-driven diseases. In this paper the recent research advance of NLRP3 inflammasome inhibitor was briefly reviewed.

Key words: NLRP3 inflammasome, disease, NLRP3 inflammasome inhibitor